Regulatory watch

Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Issues with clinical development programmes of products for psychiatry or neurology indications reviewed by the European Medicines Agency between 1995 and 2014.

Acknowledgements

The authors are grateful to M. Berntgen for his support in this project and would also like to thank O. Collignon for advice on the statistical methodology.

Author information

Correspondence to Florence Butlen-Ducuing.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information S1 (box)

Data and analysis (PDF 609 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Butlen-Ducuing, F., Pétavy, F., Guizzaro, L. et al. Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective. Nat Rev Drug Discov 15, 813–814 (2016). https://doi.org/10.1038/nrd.2016.237

Download citation

Further reading